Galapagos receives transparency notification from FMR LLC
21 August 2024 - 6:01AM
UK Regulatory
Galapagos receives transparency notification from FMR LLC
Mechelen, Belgium; 20 August
2024, 22:01 CET; regulated information – Galapagos
NV (Euronext & NASDAQ: GLPG) received a transparency
notification from FMR LLC.
Pursuant to Belgian transparency
legislation1, Galapagos received a transparency
notification on 16 August 2024 from FMR LLC, who notified that it
holds 3,696,750 of Galapagos’ voting rights, consisting of
3,693,550 ordinary shares and 3,200 equivalent financial
instruments. FMR LLC controls investment funds Fidelity Management
& Research Company LLC, FIAM LLC, Fidelity Management Trust
Company, Strategic Advisers LLC, Fidelity Institutional Asset
Management Trust Company, and FMR Investment Management (UK)
Limited, of which Fidelity Management & Research Company LLC
decreased its position to 3,259,440 voting rights and acquired
3,200 equivalent financial instruments (stock loan), FIAM LLC
increased its position to 122,898 voting rights, Fidelity
Management Trust Company decreased its position to 225,961 voting
rights, Strategic Advisers LLC decreased its position to 1 voting
right, Fidelity Institutional Asset Management Trust Company
decreased its position to 0 voting rights, and FMR Investment
Management (UK) Limited increased its position to 85,250 voting
rights.
Hence, the first-mentioned controlled
undertaking of the FMR LLC group individually crossed below the 5%
threshold. FMR LLC's holding of 3,696,750 Galapagos' voting rights,
including its controlled undertakings’ holdings, represents 5.61%
of Galapagos' currently outstanding 65,897,071 shares. FMR LLC thus
remains above the 5% threshold of Galapagos’ voting rights. The
full transparency notice is available on the Galapagos website.
About Galapagos
We are a biotechnology company with operations in Europe and the
U.S. dedicated to developing transformational medicines for more
years of life and quality of life. Focusing on high unmet medical
needs, we synergize compelling science, technology, and
collaborative approaches to create a deep pipeline of best-in-class
small molecules and cell therapies in oncology and immunology. With
capabilities from lab to patient, including a decentralized cell
therapy manufacturing network, we are committed to challenging the
status quo and delivering results for our patients, employees, and
shareholders. For additional information, please
visit www.glpg.com or follow us
on LinkedIn or X.
For further information, please
contact:
Media
inquiries:
Marieke Vermeersch
+32 479 490 603
media@glpg.com
|
Investor
inquiries:
Sofie Van Gijsel
+1 781 296 1143
ir@glpg.com
|
Jennifer Wilson
+ 44 7444 896759
media@glpg.com |
Sandra
Cauwenberghs
+32 495 58 46 63
ir@glpg.com |
1 Belgian Act of 2 May 2007 on the
disclosure of major shareholdings in issuers whose shares are
admitted to trading on a regulated market.
- GLPG Press Release FMR TN_240820_ENG
Galapagos (TG:GXE)
Historical Stock Chart
From Nov 2024 to Dec 2024
Galapagos (TG:GXE)
Historical Stock Chart
From Dec 2023 to Dec 2024